William P Vanantwerp

US Patent:

20100196439, Aug 5, 2010

Filed:

Dec 20, 2007

Appl. No.:

12/520035

Inventors:

Michael Theodore Beck - Eden Prairie MN, US
Deon Bezuidenhout - Cape Town, ZA
Kelvin Bonnema - Brooklyn Park MN, US
Kimberly A. Chaffin - Woodbury MN, US
Neil Davies - Vredehoek, ZA
Brian C.A. Fernandes - Roseville MN, US
Eric J. Fogt - Maple Grove MN, US
Eric A. Grovender - Minneapolis MN, US
Robert Cushing Hamlen - Edina MN, US
Matthew Jolly - Minneapolis MN, US
Eamonn J. McAndrew - County Galway, IE
Syamasundar V. Pakala - Blaine MN, US
William P. VanAntwerp - Valencia CA, US
Peter P. Zilla - Cape Town, ZA
Edouard A. Koullick - Golden Valley MN, US

Assignee:

Medtronic, Inc. - Minneapolis MN

International Classification:

A61K 9/00
A61K 38/18
A61K 35/12
A61P 3/10

US Classification:

424424, 514 12, 424 931

Abstract:

Various methods and devices are provided for providing therapy to a living body. In one embodiment, an implanted permeable container has living cells provided therein, and various nutrients and/or agents are provided into the container to promote cell life.

US Patent:

20120277155, Nov 1, 2012

Filed:

Feb 7, 2012

Appl. No.:

13/368285

Inventors:

William P. VanAntwerp - Valencia CA, US
Andrew J. L. Walsh - Minneapolis MN, US
VenKatesh R. Manda - Stillwater MN, US
John Burnes - Coon Rapids MN, US

Assignee:

MEDTRONIC, INC. - Minneapolis MN

International Classification:

A61K 38/22
A61M 5/142
A61M 37/00
A61P 9/04
A61P 13/12

US Classification:

514 124, 6048911, 604500

Abstract:

Medical systems and methods for treating kidney disease alone, heart failure alone, chronic kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a natriuretic peptide such as Vessel Dilator to a subject. Methods for increasing and maintaining peptide levels at a certain concentration include direct peptide delivery via either an external or implantable programmable pump.

US Patent:

52579719, Nov 2, 1993

Filed:

Mar 16, 1993

Appl. No.:

8/032037

Inventors:

Peter C. Lord - Valencia CA
William P. VanAntwerp - Westchester CA

Assignee:

MiniMed Technologies, Ltd. - Sylmar CA

International Classification:

A61M 3100

US Classification:

604 49

Abstract:

A method is provided for reconditioning a medication infusion pump by removal of accumulated medication deposits and the like to restore pump performance without requiring surgical removal of an implanted pump from a patient. The reconditioning process comprises sequential delivery of a buffer solution and a rinse solution to internal pump flow passages. The rinse solution is effective to dissolve medication deposits and the like within narrow pump flow passages before the rinse solution is neutralized by intermixing with the buffer solution. Dissolution of accumulated medication deposits results in restoration of pump performance substantially to original product specifications.

US Patent:

54337100, Jul 18, 1995

Filed:

Jun 24, 1994

Appl. No.:

8/265507

Inventors:

William P. VanAntwerp - Los Angeles CA
Virote Indravudh - Saugus CA

Assignee:

MiniMed, Inc. - Sylmar CA

International Classification:

A61M 100
F16L 500

US Classification:

604152

Abstract:

A medication infusion pump is provided for use in the programmable delivery of a selected medication to a patient, wherein the pump includes a fluoropolymer valve seat engageable with a nonmetallic valve member. The fluoropolymer valve seat defines a substantially inert and nonadherent surface to prevent accumulation of medication deposits thereon. Such deposits are believed to occur as a result of shear denaturation and/or precipitation in the vicinity of the valve seat, in response to relatively high compression forces applied to the medication as the valve member opens and closes. The fluoropolymer valve seat provides a surface which is particularly nonadherent to protein based medications, such as insulin.